We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » ReGen Denies Improper Influence in FDA’s Menaflex Clearance
ReGen Denies Improper Influence in FDA’s Menaflex Clearance
March 13, 2009
Orthopedics manufacturer ReGen Biologics has denied charges by Sen. Chuck Grassley (R-Iowa), the ranking member of the Senate Finance Committee, that it exerted improper influence over top FDA officials in the 510(k) clearance process for its Menaflex collagen scaffold.